Arab Drug (ADCI) Stock Overview
Engages in the manufacture and sale of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
ADCI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
The Arab Drug Company Competitors
October PharmaE
Alexandria For Pharmaceuticals & Chemical Industries
Kahira Pharmaceuticals & Chemical Industries
Memphis Pharmaceuticals & Chemical Industries
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م170.11 |
| 52 Week High | ج.م249.98 |
| 52 Week Low | ج.م77.65 |
| Beta | 0.35 |
| 1 Month Change | 13.79% |
| 3 Month Change | -3.89% |
| 1 Year Change | 118.09% |
| 3 Year Change | 467.51% |
| 5 Year Change | 407.49% |
| Change since IPO | 2,633.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADCI | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 0.5% | 0.2% | 4.4% |
| 1Y | 118.1% | 89.2% | 51.5% |
Return vs Industry: ADCI exceeded the EG Pharmaceuticals industry which returned 88.9% over the past year.
Return vs Market: ADCI exceeded the EG Market which returned 50.1% over the past year.
Price Volatility
| ADCI volatility | |
|---|---|
| ADCI Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in EG Market | 7.8% |
| 10% least volatile stocks in EG Market | 3.4% |
Stable Share Price: ADCI has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: ADCI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | n/a | Ahmed Ali | www.adcopharma-eg.com |
The Arab Drug Company engages in the manufacture and sale of pharmaceutical products. It offers anti-infectives, central nervous system drugs, dermatological drugs, and cardiovascular drugs, as well as animal health products in powders and solutions. The company exports its products to approximately 40 countries, including China, Korea, Turkey, Kazakhstan, Iraq, Syria, Jordan, Lebanon, Libya, Sudan, Somalia, Yemen, and Morocco.
The Arab Drug Company Fundamentals Summary
| ADCI fundamental statistics | |
|---|---|
| Market cap | ج.م2.04b |
| Earnings (TTM) | ج.م225.52m |
| Revenue (TTM) | ج.م1.23b |
Is ADCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADCI income statement (TTM) | |
|---|---|
| Revenue | ج.م1.23b |
| Cost of Revenue | ج.م737.24m |
| Gross Profit | ج.م496.51m |
| Other Expenses | ج.م270.99m |
| Earnings | ج.م225.52m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.79 |
| Gross Margin | 40.24% |
| Net Profit Margin | 18.28% |
| Debt/Equity Ratio | 88.1% |
How did ADCI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/19 16:19 |
| End of Day Share Price | 2026/04/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Arab Drug Company is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mohamed Hamza | Pharos Research |